CLINICAL TRIALS of Gilead Sciences’ remdesivir have begun in Wuhan, China, the center of the novel coronavirus outbreak, a day after Chinese researchers recommended that the antiviral drug candidate remdesivir be assessed in humans as a potential treatment for 2019-nCoV.
China’s National Medical Products Administration has approved applications by the China-Japan Friendship Hospital and the Chinese Academy of Medical Sciences to conduct trials evaluating remdesivir.
China’s National Medical Products Administration has approved applications by the China-Japan Friendship Hospital and the Chinese Academy of Medical Sciences to conduct trials evaluating remdesivir.
